Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Dalbavancin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for dalbavancin hydrochloride?

Dalbavancin hydrochloride is the generic ingredient in one branded drug marketed by Durata Theraps Intl and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has fifty-three patent family members in sixteen countries.

One supplier is listed for this compound.

Summary for Generic Name: dalbavancin hydrochloride

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Drug Master File Entries: 0
Suppliers / Packagers: see list1
Clinical Trials: see list991
Drug Prices:see low prices
DailyMed Link:dalbavancin hydrochloride at DailyMed

Pharmacology for Ingredient: dalbavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Durata Theraps Intl
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► Subscribe
Durata Theraps Intl
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes8,143,212► Subscribe ► Subscribe
Durata Theraps Intl
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes6,900,175► Subscribe ► Subscribe
Durata Theraps Intl
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes7,119,061► SubscribeY ► Subscribe
Durata Theraps Intl
DALVANCE
dalbavancin hydrochloride
POWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes7,115,564► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dalbavancin hydrochloride

Country Document Number Estimated Expiration
South Korea100930982► Subscribe
South Africa200607888► Subscribe
World Intellectual Property Organization (WIPO)2004045637► Subscribe
Australia2011200423► Subscribe
Japan2007534768► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc